News for Erasca, Inc. (ERAS)

Erasca, Inc. (ERAS) has received approval from the U.S. Food and Drug Administration (FDA) for its investigational new drug application for ERAS-4001, a promisi

Both ERAS-4001 and potential best-in-class pan-RAS molecular glue ERAS-0015 received IND clearance in May ahead of company guidance Initial Phase 1 monotherapy

SAN DIEGO, May 29, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. ( ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, a

Guggenheim analyst Michael Schmidt has revised the price target for Erasca (ERAS), setting it at $3, down from the previous $3.50. Despite the reduction, Schmid

Early entry of RAS-targeting franchise into clinic enabled by strong execution Initial Phase 1 monotherapy data for pan-RAS molecular glue ERAS-0015 and pan-KR

SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. ( ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, a

Erasca (ERAS) has unveiled compelling preclinical data at the American Association for Cancer Research meeting in Chicago, highlighting the promising profiles o

**media[609520]**

Erasca continues developing novel RAS-pathway cancer drugs, backed by funding through 2027 and promising early results. Find out why ERAS stock is a buy.

U.S. stocks were lower, with the Dow Jones index falling around 700 points on Monday. Shares of Wolverine World Wide, Inc. WWW rose sharply during Monday's ses...

We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Erasca Inc. (NASDAQ:ERAS) stands against other biotech penny stocks. Peter Marks’s departure from the FDA has left innovators concerned regarding the current state of the […]

Peter Marks's departure from the FDA has left innovators concerned regarding the current state of the review program at the FDA. Marks had impacts on two key areas.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

**media[576521]**

Cash Position: Ended 2024 with $440.5 million in cash, cash equivalents, and marketable securities, up from $322.0 million at the end of 2023.Net Loss: Reporte

Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025 Ongoing Phase 3 SEACRAFT-2 r

**media[572468]**

On December 31, 2024, SILVERARC CAPITAL MANAGEMENT, LLC (Trades, Portfolio) made a significant move by acquiring an additional 136,463 shares of Elutia Inc, a c

**media[528995]**